MAM
BMRN icon

Myriad Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Myriad Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,200
Closed -$431K – 64
2016
Q4 		$431K Buy
+5,200
New +$447K 0.03% 52

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Myriad Asset Management's BMRN Position: Q1 2017 in Review

Myriad Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 5,200 shares — an estimated $431K sold.

Myriad Asset Management first reported a position in BMRN in Q4 2016 and held it in 1 quarter. The position peaked at $431K in Q4 2016. 417 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

  • Myriad Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Myriad Asset Management sold 5,200 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $431K.
  • Myriad Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Myriad Asset Management's BioMarin Pharmaceuticals position peaked at $431K in Q4 2016.
  • 417 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Myriad Asset Management's 13F filing for Q1 2017, filed 12 May 2017.